

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human RNF43 in direct ELISAs.
Source	Recombinant Monoclonal Mouse IgG ₁ Clone # 923227R
Purification	Protein A or G purified from cell culture supernatant
Immunogen	Human embryonic kidney cell line HEK293-derived recombinant human RNF43 Glu43-Val199 Accession # Q68DV7
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	HEK293 Human Cell Line Transfected with Human RNF43 and eGFP

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> ● 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

RING finger protein 43 (RNF43) is a 90 kDa member of the ZNRF3 family of ubiquitin ligase proteins (1, 2). Human RNF43 is synthesized as a 783 amino acid (aa) protein that contains a putative 23 aa signal sequence, a 174 aa extracellular domain (ECD), a transmembrane domain, and a cytoplasmic domain with an atypical RING-type zinc finger (1). RNF43 is expressed in stem cells at the bottom of colon crypts, where it limits the ability of Wnts to induce proliferation (3). RNF43 and ZNRF3, another transmembrane E3 ubiquitin ligase, ubiquitinate and promote the turnover of Frizzled Wnt receptors to antagonize Wnt signaling (3, 4). RNF43 has been shown to suppress both canonical and non-canonical Wnt signaling pathways by distinct mechanisms (5). RNF43/ZNRF3-mediated turnover of Frizzled receptors is inhibited by R-Spondin (4). Dishevelled, a positive regulator of Wnt signaling, interacts with RNF43/ZNRF3 to mediate turnover of Frizzled receptors (6). RNF43 may promote cell survival by binding to NEDL1 and by suppressing the transcriptional activity of p53 (7, 8). RNF43 has been shown both to inhibit and promote cancer. Deletion of RNF43, as well as mutations found in colorectal and other cancers, allows hypersensitivity to Wnts and promotes adenoma formation (3, 9). Furthermore, RNF43 down-regulation in gliomas is associated with poor prognosis (10). However, RNF43 is frequently over-expressed in cancers, correlating with growth-promoting activity and colorectal and hepatocellular cancer pathogenesis (1, 7, 11).

References:

1. Yagyu, R. *et al.* (2004) *Int. J. Oncol.* **25**:1343.
2. de Lau, W. *et al.* (2014) *Genes Dev.* **28**:305.
3. Koo, B.K. *et al.* (2012) *Nature* **488**:665.
4. Hao, H.X. *et al.* (2012) *Nature* **485**:195.
5. Tsukiyama, T. *et al.* (2015) *Mol. Cell. Biol.* **35**:2007.
6. Jiang, X. *et al.* (2015) *Mol. Cell* **58**:522.
7. Xing, C. *et al.* (2013) *Mol. Cancer Ther.* **12**:94.
8. Shinada, K. *et al.* (2011) *Biochem. Biophys. Res. Commun.* **404**:143.
9. Giannakis, M. *et al.* (2014) *Nat. Genet.* **46**:1264.
10. Xi, S. *et al.* (2015) *Int. J. Clin. Exp. Pathol.* **8**:490.
11. Uchida, N. *et al.* (2004) *Clin. Cancer Res.* **10**:8577.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.